Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study

NCT00054184 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00054184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00054184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2003
Completion date
October 31, 2004
Enrollment
350 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer